Testicular germ cell tumours are classified into two major histological subgroups, seminomas and nonseminomas. All tumours display several recurrent chromosomal aberrations, but few target genes have been identified. Previous studies have shown that genome-wide hypermethylation of CpG islands is significantly more prevalent in nonseminomas than in seminomas. We have studied two potential target genes in testicular cancer. A series of 70 tumours were analysed for methylation of CpG sites in the O 6 -methylguanine-DNA methyltransferase (MGMT) gene promoter, and in exon 1a of the cyclin-dependent kinase inhibitor 2A gene (CDKN2A). In addition, eight microsatellite markers within and flanking these genes at chromosome arms 10q and 9p, respectively, were analysed for allelic imbalances. Allele alterations were frequently seen at 9p loci (47 out of 70, 67%), but none of the tumours (none out of 55) showed methylation of CDKN2A. On the other hand, a high frequency of MGMT promoter methylation (32 out of 69, 46%) was found, as well as allelic imbalances at 10q markers (50 out of 70, 71%). A significantly higher methylation frequency was found in nonseminomas (24 out of 35, 69%) compared to seminomas (eight out of 33, 24%) (P=0.0003, Fisher's exact test). Immunohistochemical analysis of the MGMT protein in a subgroup (n=20) of the testicular tumours supported the hypothesis of gene silencing being the functional consequence of the promoter methylation. In summary, our data suggest that inactivation of MGMT contributes to development of nonseminomatous testicular cancer.
Introduction
Testicular cancer is the most common cancer among young and adolescent Caucasian men and is usually of germ cell origin. Testicular germ cell tumours (TGCT) are divided into two major histological subgroups, seminomas and nonseminomas, both suggested to arise from the precursor stage carcinoma in situ. Nonseminomas contain either embryonal carcinoma, teratoma, yolk sac elements, choriocarcinoma, or a mixture of these components. Today, more than 90% of patients with newly diagnosed TGCT are cured from the disease, and only 10 to 20% of patients with metastatic tumours at time of diagnosis do not become permanently tumour-free (Josefsen et al., 1993) .
In addition to the characteristic cytogenetic aberration isochromosome 12p, a number of recurrent DNA sequence changes and chromosome aberrations have been found in TGCT (Atkin and Baker, 1982; Castedo et al., 1989a,b; Heidenreich et al., 2000; Lothe et al., 1993; Murty and Chaganti, 1998; Skotheim et al., 2001a) . Nevertheless only few genes contributing to the development of this disease have been identified (Looijenga et al., 1999; Kraggerud et al., 2002; Skotheim et al., 2002) .
Methylation imbalance is one of several characteristic features of tumorigenesis. Hypermethylation of CpG sites in promoter regions may result in transcriptional silencing of the genes in question (Baylin and Herman, 2000; Baylin et al., 1998) . Genome-wide studies of tumour-associated methylation by restriction landmark genome scanning (RLGS), have revealed a significant difference between seminomas and nonseminomas in the overall methylation pattern (Costello et al., 2000; Smiraglia et al., 1999 Smiraglia et al., , 2002 . The tumour suppressor gene, CDKN2A (p16 INK4A ), and the repair enzyme gene, MGMT, are both known targets for methylation inactivation in other cancer types, but their role in TGCT is not known (Esteller, 2000) .
The incidence of hypermethylation of the CpG island in the 5' region of the CDKN2A gene range from 20 to 40% among different types of solid tumours. Together with the incidence of homozygous deletions, this gene rivals TP53 as the most frequently inactivated tumour suppressor gene in cancer (Baylin et al., 1998) . The p16
INK4a protein inhibits the catalytic activity of CDK/cyclin D complexes and is thereby involved in the control of cell cycle progression from G 1 to S-phase (Serrano et al., 1993) . The CDKN2A gene maps to 9p21 (Kamb et al., 1994; Nobori et al., 1994) , and loss of heterozygosity at 9p21 loci, implying loss of one CDKN2A allele, has been reported for TGCT (Heidenreich et al., 1998; Murty et al., 1994) . Whether 5'-CpG methylation may contribute to silence the CDKN2A gene in TGCT remains unclear (Chaubert et al., 1997; Heidenreich et al., 1998) .
To our knowledge methylation of MGMT has not been investigated in TGCT. Cells are normally protected from promutagenic O 6 -methylguanine alkylation by the action of MGMT (Pegg et al., 1995) . MGMT maps to chromosome band 10q26, a region corresponding to the Tgct-1 locus in a mouse model used to study susceptibility of TGCT (Matin et al., 1999) .
We have addressed the potential involvement of MGMT and CDKN2A in testicular tumorigenesis by performing 5'-CpG methylation and allelic imbalance (AI) assays in a series of primary tumours.
Results

CpG methylation of MGMT and CDKN2A
The analysed CpG sites upstream of the coding region of MGMT were methylated in 32 out of 69 tumour samples, 46% (Figure 1 ). The amount of PCR products generated by the methylation-specific primer set varied among the different samples. Samples scored as + and ++ relative to the positive control are illustrated in Figure 1 . Tumour specimens scored as methylation positive samples gave sometimes also rise to specific unmethylated products. Both heterogeneity within tumour samples as well as infiltrating normal cells can contribute to this outcome. The number of methylated MGMT samples was significantly higher in nonseminomas (24 out of 35, 69%) compared to seminomas (eight out of 33, 24%). This finding was independent of scoring method (+ or ++), see Table  1 . Five of the eight positive seminoma samples with methylated MGMT were taken from pure seminomas, whereas three were from nonseminomas containing seminomatous elements. Only the latter cases showed methylation at a ++ level within the group of seminomas. As expected, no product was obtained from the methylation-specific PCR analysis of the normal testis tissue sample used as negative control. Neither methylation-specific PCR products nor products from unmethylated targets were obtained from the carcinoma in situ sample collected from a patient with seminoma. The other carcinoma in situ sample obtained from a patient with nonseminoma had no methylation of the MGMT gene.
The results of methylation analysis at CpG sites in the CDKN2A gene were scorable for 55 TGCT samples, including 25 samples with methylated sites in MGMT (consisting of 19 nonseminomas and six Figure 1 Methylation status of MGMT and CDKN2A in TGCT. Methylation status of four nonseminomas (NS1-NS4), one normal testis sample (N), a negative PCR control (neg), and methylated placenta DNA as a positive control (MePla) are illustrated. Size marker jX174 DNA -HaeIII is included in the left line of each gel. PCR products in the methylated panels indicate samples with methylated CpG sites. Positive MGMT methylation status was scored according to relative band intensity compared with the positive control sample. Methylated CpG sites ++ have equal or stronger band intensity than the positive control, as seen for sample NS1. Methylated CpG sites + denotes a band less intense than the positive control, as seen for NS2 and NS3. Unmethylated CpG sites, meaning no visual PCR product, were found for NS4 and N in the MGMT panel, and for all samples in the CDKN2A panel except for the positive control T47D 
Allelic imbalance analyses
The frequencies of tumours with AI at one or more loci at 9p21 -22 or 10q26 were 67% and 71%, respectively. Representative samples are illustrated in Figure 2 . When AI was present, it was usually seen at all informative loci along the same chromosomal region. There was no significant difference between the frequencies of imbalances in seminomas versus nonseminomas. Twenty-four out of 33 seminomas (73%) had AI at 9p21 -22 versus 22 out of 35 nonseminomas (63%) (P=0.4). At 10q26, 26 out of 33 seminomas (79%) versus 23 out of 35 nonseminomas (66%) had AI (P=0.3).
Comparison of methylation status and allelic imbalance
Methylation status of the MGMT gene was compared to AI results for markers at 10q26, see Table 2 . Among the 24 nonseminomas with methylated MGMT promoter, 17 showed AI at markers surrounding the gene (71%). In comparison, six out of 11 unmethylated nonseminomas had AI (55%). Among seminomas with methylated CpG sites, six out of eight samples had AI (75%), whereas in the group of unmethylated semi- Figure 2 Allelic imbalance at 9p21 -22 and 10q26 loci in TGCT. Loss of alleles at microsatellite loci located to chromosome bands 9p21 -22 and 10q26 is illustrated for two patients in the upper and lower panels, respectively. The genotype pattern is shown for constitutional and tumour DNA in each case. Peak heights reflecting the allele intensities in relative fluorescence units (y-axis) are given below each allele. The degree of allelic imbalance, calculated as Q LOH , is shown for each locus. Note that constitutional homozygosity was found at D10S169 nomas 20 out of 25 samples had AI (80%). No significant relation between methylation status and AI was found.
MGMT protein expression
Twenty of the TGCT were analysed by immunohistochemistry using an anti-MGMT antibody. Normal testicular tissues next to the tumours stained positive. Among the 13 TGCT not methylated in the MGMT promoter, seven had lost their MGMT protein expression (54%), whereas among the seven tumours methylated in the MGMT promoter, six had loss of expression (86%; P=0.18, one-sided Fisher's exact test). The methylated tumour with positive immunostaining was a nonseminoma expressing MGMT in its teratoma and yolk sac tumour components, but not in its embryonal carcinoma component.
Discussion
The present study is to our knowledge the first report on methylation of MGMT in testicular cancer. Aberrant methylation was observed in nearly half of the TGCT samples (32 out of 69), a frequency somewhat higher than previously reported for primary gliomas and colorectal carcinomas, two malignancies that have the highest known frequencies of hypermethylated MGMT (each approximately 40%) (Esteller et al., 1999) . Indeed, this makes MGMT one of the most frequently altered genes identified in TGCT. Abnormal methylation of CpG sites in the promoter region can explain down-regulated MGMT expression in tumours with suppressed gene activity, with no evidence of large gene deletions or rearrangements. It is still unknown which of the CpG sites in the 5'-flanking region that need to be methylated, or how dense the methylation must be in order to silence gene expression. Studies have indicated that the specific methylation pattern as well as the degree of methylation may differ among samples (Costello et al., 1994; Qian et al., 1995) . Detailed analyses of two cell lines have indicated hot spot regions from 7249 to 7103, and from +107 to +196 base pairs relative to the transcription start site (Qian and Brent, 1997) . Further studies of more cell lines and xenografts have confirmed the association between methylation at certain CpG sites and lack of MGMT expression (Danam et al., 1999) . One of the five CpG sites tested by Danam et al. (1999) is included in the regions screened in the present study, and the primer sites used are located within the designated hot spot region from +107 to +196. This region overlaps with an enhancer element of 59 base pairs previously reported to be necessary for efficient MGMT promoter function (Harris et al., 1994) . Although less investigated than promoter methylation, methylation of some sites within the body of the gene may influence and be required for MGMT expression (Costello et al., 1994; Bearzatto et al., 2000) . The fact that six out of seven methylated tumours of the present series had lost their MGMT protein expression support the view that the epigenetic changes detected cause gene silencing.
In addition to the relatively high overall MGMT methylation frequency in the present series, a significant difference in methylation was found between nonseminomas and seminomas. This cannot be due to differences in gene copy number since previous cytogenetic studies have reported a comparable low frequency of changes at chromosome arm 10q between the two subgroups. Indeed, a recent comparative genomic hybridization study of 33 TGCT, of which 30 are included in the present study, showed gain of 10q26 in only two seminomas and in two nonseminomas . The present data of AI at 10q showed a much higher frequency of 10q changes than the cytogenetic data, possibly due to the different resolution levels of the two methods, but also by this methodological approach no clear difference between the two histological subgroups was found. It is therefore reasonable to assume that methylation of MGMT takes place during the transition from seminoma to nonseminoma, in line with the linear developmental model from carcinoma in situ, via seminoma into nonseminoma (Faulkner et al., 2000; Oosterhuis et al., 1989) . A comparable situation has been reported for brain tumours (Nakamura et al., 2001) . MGMT methylation was significantly more frequent in glioblastomas that had progressed from low-grade astrocytomas than in primary glioblastomas. However, the possibility remains that nonseminoma develops directly from a carcinoma in situ. Additional analysis of carcinoma in situ samples should provide further insights into the developmental model of TGCT.
The repair protein MGMT is able to remove alkyl groups from O 6 -guanine by an irreversible transfer to an internal cysteine residue. Increased repair may contribute to lower a cell's sensitivity for, or development of resistance to, chemotherapy. Chemotherapy against malignant TGCT is based on cisplatin often in 
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Methylation of MGMT in testicular germ cell tumours B Smith-Sørensen et al combination with etoposide and bleomycin, and ifosfamide may be added when suboptimal response is observed. Ifosfamide is the only alkylating drug among these chemo-therapeutica, but its cytotoxic effect does not seem to be influenced by MGMT activity (Preuss et al., 1996) . It remains to be seen whether MGMT status is useful for identifying TGCT with specific chemo-sensitivity for certain alkylating agents. Interestingly, Esteller et al. (2000) reported an association between methylation of CpG sites in the MGMT gene, and responsiveness to carmustine for patients with gliomas. Inactivation of growth-restricting genes may cause cells to proliferate more rapidly and therefore give them a selective advantage. Transcriptional repression of the CDKN2A gene by hypermethylation of 5'-CpG sites has specifically been seen in primary tumours and not in corresponding normal tissues . The methylation assays used in the present study is limited to detection of CpG methylation status within short regions recognized by specific primers for unmethylated and methylated DNA templates. A strong inverse association has been reported between methylation detected by this assay and p16
INK4a
protein expression (Shim et al., 2000) . Whether or not all CpG sites within each primer recognition site need to be methylated to obtain the PCR product may be sequence dependent, but methylation at CpG sites close to the elongation point is most likely a requirement. We have previously detected methylation within the CDKN2A gene in cases where subsequent sequence analysis confirmed complete CpG methylation (unpublished results). Thus, partial methylation will most likely not be detected by this approach and may explain the absence of CDKN2A methylation in the present series. The two other studies of CDKN2A gene methylation in TGCT samples both used restriction enzyme digestions to test for methylation in three CpG sites. In accordance with our findings, Heidenreich et al. (1998) did not find complete methylation in any of the tested samples, whereas Chaubert et al. (1997) reported methylation in 13 out of 26 samples without emphasizing whether or not the methylation patterns were complete.
In a cytogenetic survey of more than 3000 neoplasms, including 209 TGCT, net loss of chromosome arm 9p was deduced from each karyotype in about 30% of the TGCT (Mertens et al., 1997) . The same frequency was found by comparative genomic hybridization among some of the tumours (n=30) included in the present study . AI at 9p loci has previously been reported in two rather small TGCT series (Chaubert et al., 1997; Heidenreich et al., 1998) . The high frequency of AI at 9p loci in the present series is in line with the findings of Heidenreich et al. (1998) . Among 17 tumours, AI was found in 59% at one or more of five 9p markers, including two of the markers used in our study. In the other paper, no 9p losses were reported among 14 constitutionally heterozygous cases (Chaubert et al., 1997) .
The present data suggest that alterations of MGMT contribute to development of the nonseminomatous histological subgroup of TGCT.
Materials and methods
Samples
Blood and primary tumour samples were obtained from 70 Norwegian patients with TGCT. The frozen tumour sample from each patient was sliced and three sections were stained with hematoxylin and eosin in order to estimate the fraction of intact neoplastic tissue. Across the sample set, an average of 75% neoplastic tissue was observed (range: 30 to 100%). The remaining tissue from each frozen sample was submitted to DNA extraction. Genomic DNA was isolated from blood and tumour samples in a 340A Nucleic Acid Extractor (Applied Biosystems, Foster City, CA, USA), applying standard phenol/chloroform extraction followed by ethanol precipitation. All frozen tumour samples were classified according to WHO recommendations (Mostofi and Sobin, 1976) . Thirty-three of the samples were seminomas (25 were from patients with a pure seminoma and eight were from patients with mixed tumours (nonseminoma and seminoma components), 35 were nonseminomas, and two samples were carcinomas in situ (one represented carcinoma in situ nearby a seminoma, and the other was taken from testicular tissue surrounding a nonseminoma).
Methylation-specific PCR
DNA samples submitted to methylation analyses were modified according to the protocol of the CpGenome TM DNA modification kit (InterGen, Boston, MA, USA). Two mg DNA was used as a starting amount and each treated sample was resuspended in 50 ml 16TE, pH 7.5. DNA methylation status in the CpG islands of MGMT and CDKN2A were determined by subsequent PCR, using different primer sets specific for methylated and unmethylated CpG sites. Previously described primer sets were used for amplification of both MGMT fragments (Esteller et al., 1999) and CDKN2A fragments (Herman et al., 1996) .
The MGMT fragments were amplified with 22.5 pmol of each primer, except for the anti-sense primer for unmethylated DNA where 5.6 pmol was used. The reaction mixtures contained 1.0 mM MgCl 2 and 5 ml modified DNA solution as template. PCR was initiated by 7 min heating at 958C, followed by 35 cycles of 958C for 45 s, 588C for 30 s and 728C for 30 s, and ending by 7 min at 728C. Human placental DNA (Sigma Chemical Co., St. Louis, MO, USA) treated in vitro with SssI methyltransferase (New England Biolabs Inc., Beverly, MA, USA) was the positive control for methylated templates, whereas DNA from normal testis tissue was used as the negative control. Methylation positive samples were visually scored as + or ++. Samples in the ++ group were reproducibly amplified to an equal or higher intensity compared to the positive control of methylated DNA. The remaining positive samples, the + group, constituted reproducible methylated PCR products with less intensity than the positive control.
CDKN2A fragments were amplified with 25 pmol of each primer (Herman et al., 1996) . Each reaction contained 1.5 mM MgCl 2 and 2 ml modified DNA solution as template. The PCR program was as described above, except for the 648C annealing temperature for unmethylated, and 638C for methylated DNA templates, and the 1 min long cycle steps. The human cell line T47D, earlier reported to harbour a methylated 5'-CpG island in CDKN2A Hui et al., 2000) , was the positive control. Again, DNA from normal testis tissue was the negative control.
All PCR reactions contained the following reagents: GeneAmp 16PCR Buffer II (Applied Biosystems), 200 mM dNTP (Amersham Pharmacia Biotech Products Inc., Piscataway, NJ, USA), and 2.5 U AmpliTaq DNA Polymerase (Applied Biosystems). PCR was performed in volumes of 50 ml using a GeneAmp PCR System 2400 (Applied Biosystems). The PCR products were analysed by running 7.5% PAGE, and stained with ethidium bromide before photographing using an UV transilluminator. All samples interpreted as methylated were confirmed by at least one additional round of PCR. Except for two samples, all cases analysed for promoter hypermethylation in MGMT were also tested for CDKN2A methylation. Two to six independent attempts were done to amplify CDKN2A fragments. For 13 samples limited access to tumour DNA restricted further efforts to obtain test results of CpG methylation in CDKN2A.
Allelic imbalance analyses
Eight polymorphic microsatellite loci, i.e. D10S1483, D10S1651, D10S1700 and D10S169, mapping to chromosome band 10q26, and D9S157, D9S171, D9S161 and D9S165, at 9p21 -22, were analysed for AI (UCSC Genome Browser, April 2002 freeze, http://genome.ucsc.edu/). The analyses were performed as previously described (Skotheim et al., 2001a,b) . Briefly, the fragments were amplified by PCR with 2 -4.4 pmol of each primer and 50 ng DNA. The reaction contained 1.5 mM MgCl 2 . One primer in each pair was 5'-tagged with a fluorochrome (HEX, TET, or 6-FAM), and two or three markers were amplified together. All primer sequences were electronically accessible from the GDB (Human Genome Database, Baltimore, MD, USA; http:// gdbwww.gdb.org/). The samples were run on an ABI PRISM TM 310 Genetic Analyzer (Applied Biosystems). A semi-quantitative determination of the degree of AI, Q LOH , was subsequently calculated from the measured peak heights by dividing the allele ratio in tumour DNA by the allele ratio in corresponding normal (blood) DNA. The cut-off level for AI scoring by this fluorescent primer protocol has previously been determined to Q LOH 40.84 based on the variance of repeated analyses of 485 constitutional heterozygous genotypes at 20 different microsatellite loci (Skotheim et al., 2001b) . A tumour sample is denoted AI if one or more of the four markers within the same chromosome region is registered with AI.
Immunohistochemistry
The MGMT protein expression was analysed by immunohistochemistry on formalin fixed and paraffin embedded tissues from twenty of the same tumours (seven methylated and 13 not methylated; nine seminomas and 11 nonseminomas). The biotin -streptavidin amplified system using the Optimax1 Automated Cell Staining System Plus (BioGenex, San Raman, CA, USA) was applied for immunohistochemistry of 4 mm tissue sections. After deparaffinization and rehydration, high temperature antigen retrieval was performed by three times 5 min microwaving at 900 W in 2 mM citrate buffer, pH 6.0. Incubation with 1% hydrogen peroxide (H 2 O 2 ) for 10 min was used to block the endogenous peroxidase activity before 30 min incubation in room temperature with the primary antibody (1 : 200 goat polyclonal anti-MGMT, sc-8825, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The tissues were then incubated for 20 min with multilink biotinylated anti-immunoglobulins (1 : 30; BioGenex) and 20 min with streptavidin peroxidase (1 : 30; BioGenex). Further the sections were stained for 5 min with 0.05% of the peroxidase substrate 3k,3-diaminobenzidine tetrahydrochloride (DAB) freshly prepared in 0.05 M Tris-HCl buffer at pH 7.6 containing 0.01% H 2 O 2 , before being counterstained with haematoxylin, dehydrated, and mounted. The immunostaining was nuclear, and cases with staining of more than 5% of the nuclei were considered positive.
Statistical analysis
Contingency tables were analysed by Fisher's exact test. Pvalues less than 0.05 were considered statistically significant.
